Brief: Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation
16/06/2026 10:09
BRIEF-Mabion Signs Deal With Oddifact Sas On Preparing Mabioncd20 For FDA Consultation June 16 (Reuters) - Mabion SA MABP.WA:
SIGNS AGREEMENT WITH ODDIFACT SAS FOR FIRST STAGE OF COOPERATION ON PREPARING MABIONCD20 FOR FDA CONSULTATION
POTENTIAL ANNUAL MARKET VALUE OF CD20 TREATMENT IN U.S. ESTIMATED AT $100 MILLION
FOLLOWING DEAL COMPANY REVERSES 4.8 MILLION ZLOTY INVENTORY WRITE-DOWN
Source text: ID:nEM5yMqbMa
Further company coverage: MABP.WA
(Reporting by Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com;))
Recent news on Mabion SA
See all newsBrief: Mabion Partner Oddifact Says FDA Consultations Allow MabionCD20 To Be Used As First-Line Therapy For ITP
Brief: Mabion Holds Pre-IND Type B Meeting With FDA On MabionCD20 Development For ITP
Brief: Mabion Signs LoI With WPD Pharmaceuticals On Extension Of Cooperation
Brief: Mabion Q2 Net Loss At 15 Mln Zlotys
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects